• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Veru Inc.

    12/12/24 12:07:55 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERU alert in real time by email
    POS AM 1 d814466dposam.htm POS AM POS AM

    As filed with the Securities and Exchange Commission on December 12, 2024.

    Registration Statement No. 333-271891

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1

    to

    FORM S-3

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    VERU INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Wisconsin     39-1144397

    (State or Other Jurisdiction of

    Incorporation or Organization)

       

    (I.R.S. Employer

    Identification Number)

    2916 North Miami Avenue

    Suite 1000

    Miami, Florida 33127

    (305) 509-6897

    (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

     

     

    MITCHELL S. STEINER, M.D.

    Chairman, President and Chief Executive Officer

    Veru Inc.

    1000 North Miami Avenue

    Suite 1000

    Miami, Florida 33127

    Telephone (305) 509-6897

    (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)

     

     

    Copies of communications to:

    Benjamin G. Lombard, Esq.

    Reinhart Boerner Van Deuren s.c.

    1000 North Water Street, Suite 1700

    Milwaukee, Wisconsin 53202

    (414) 298-1000

     

     

    Approximate date of commencement of proposed sale to the public: Not applicable.

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large Accelerated Filer   ☐    Accelerated Filer   ☐
    Non-Accelerated Filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

     

     

     


    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment relates to the registration statement on Form S-3, Registration No. 333-271891 (the “Registration Statement”), filed by Veru Inc. (the “Company”) on May 12, 2023 with the Securities and Exchange Commission (the “Commission”) to register the sale by a selling shareholder from time to time of up to 5,000,000 shares of the Company’s common stock, par value $0.01 per share (the “Registered Securities”). The Registration Statement was declared effective by the Commission on May 24, 2023.

    The Company has decided to terminate the offerings under the Registration Statement. Accordingly, the Company is filing this Post-Effective Amendment to the Registration Statement to terminate the effectiveness of the Registration Statement, and, in accordance with the undertakings made by the Company in the Registration Statement, to remove from registration any and all of the Registered Securities that remain unsold as of the date hereof. The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of all such securities.

     

    2


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Miami, State of Florida on the 12th day of December, 2024.

     

    VERU INC.
    BY  

    /s/ Mitchell S. Steiner

      Mitchell S. Steiner, M.D.
      Chairman, President and Chief Executive Officer

    No other person is required to sign this Post-Effective Amendment to the Registration Statement in reliance on Rule 478 under the Securities Act of 1933, as amended.

     

    3

    Get the next $VERU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VERU

    DatePrice TargetRatingAnalyst
    12/18/2025$25.00Buy
    Canaccord Genuity
    5/14/2024$5.00Buy
    B. Riley Securities
    3/28/2024$3.00Outperform
    Raymond James
    6/7/2023$1.00Underperform → Hold
    Jefferies
    More analyst ratings

    $VERU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rankowitz Michael L bought $84,351 worth of shares (150,000 units at $0.56), increasing direct ownership by 150% to 250,000 units (SEC Form 4)

    4 - VERU INC. (0000863894) (Issuer)

    2/20/25 10:00:11 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fisch Harry bought $5,000 worth of shares (4,000 units at $1.25), increasing direct ownership by 0.52% to 774,736 units (SEC Form 4)

    4 - VERU INC. (0000863894) (Issuer)

    5/28/24 5:04:02 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barnette K Gary bought $6,696 worth of shares (5,000 units at $1.34) (SEC Form 4)

    4 - VERU INC. (0000863894) (Issuer)

    5/24/24 6:57:00 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    SEC Filings

    View All

    SEC Form 10-Q filed by Veru Inc.

    10-Q - VERU INC. (0000863894) (Filer)

    2/11/26 10:32:14 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - VERU INC. (0000863894) (Filer)

    2/11/26 7:00:14 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Veru Inc.

    DEFA14A - VERU INC. (0000863894) (Filer)

    1/28/26 4:07:48 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

    -- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 first quarter ended December 31, 2025, and provided a corporate update. "The strategy for the next generation of obesity drugs should be a combination therapy with GLP-1 receptor agonists for

    2/11/26 6:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

    MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, February 11, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 first quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru I

    2/4/26 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

    -- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an acceptable approvable primary endpoint with key secondary endpoints on physical function and body composition improvements -- -- Company plans to initiate Phase 2 PLATEAU clinical study in calendar Q1 2026 -- -- Post fiscal year end, company completed public offering for net proceeds of approximately $23.4 million -- -- Company to host conference call and webcast today at 8:00 a.m. ET -- MIAMI, FL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceu

    12/17/25 6:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Scientific Officer Barnette K Gary

    4 - VERU INC. (0000863894) (Issuer)

    12/9/25 12:29:58 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Rankowitz Michael L

    4 - VERU INC. (0000863894) (Issuer)

    12/9/25 12:19:11 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Katzovitz Loren Mark

    4 - VERU INC. (0000863894) (Issuer)

    12/9/25 12:10:02 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ENTADFI issued to VERU INC

    Submission status for VERU INC's drug ENTADFI (ORIG-1) with active ingredient FINASTERIDE;TADALAFIL has changed to 'Approval' on 12/09/2021. Application Category: NDA, Application Number: 215423, Application Classification: Type 4 - New Combination

    12/13/21 8:12:46 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Veru with a new price target

    Canaccord Genuity initiated coverage of Veru with a rating of Buy and set a new price target of $25.00

    12/18/25 9:11:57 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Veru with a new price target

    B. Riley Securities initiated coverage of Veru with a rating of Buy and set a new price target of $5.00

    5/14/24 8:03:44 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Veru with a new price target

    Raymond James initiated coverage of Veru with a rating of Outperform and set a new price target of $3.00

    3/28/24 7:50:24 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Leadership Updates

    Live Leadership Updates

    View All

    Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board

    MIAMI, FL, June 01, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced the appointment of Erik Swenson, M.D., a world-renowned pulmonologist specializing in critical care, and Robert Schooley, M.D., an accomplished infectious disease physician and researcher, to its Infectious Disease Scientific Advisory Board (SAB) to join David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, who is Chairman of the SAB. "We are pleased to share that Dr. Erik Swenson and

    6/1/23 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board

    MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced the appointment of David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, as Chairman of its Scientific Advisory Board (SAB). "Today's appointment of Dr. Ho as Chairman of Veru's SAB illustrates our commitment to building a team of scientific experts to support our goal of developing and delivering life-saving therapies to patients with COVID-19 and other viral ARDS-related diseases," said Mitchell Steiner, M.D., Chairman, Presi

    1/10/23 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients

    MIAMI, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Jason Davies as Executive Vice President – General Manager of Europe, the Middle East and Africa (EMEA), Latin America (LATAM), and Asia Pacific (APAC) for Veru's Infectious Disease Franchise for Veru International. Most recently Mr. Davies had been the EMEA Head of Launch Excellence – Pharmaceutical Portfolio at Janssen (Johnson & Johnson) where he was responsible for creating and leading a new organization to enhan

    8/19/22 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Veru Inc.

    SC 13G/A - VERU INC. (0000863894) (Subject)

    11/12/24 9:34:37 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veru Inc.

    SC 13G/A - VERU INC. (0000863894) (Subject)

    11/4/24 4:19:00 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Veru Inc.

    SC 13G - VERU INC. (0000863894) (Subject)

    4/24/24 4:16:01 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Financials

    Live finance-specific insights

    View All

    Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

    -- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 first quarter ended December 31, 2025, and provided a corporate update. "The strategy for the next generation of obesity drugs should be a combination therapy with GLP-1 receptor agonists for

    2/11/26 6:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

    MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, February 11, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 first quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru I

    2/4/26 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru to Report Fiscal Year 2025 Financial Results on December 17th

    MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, December 17, 2025, at 8:00 a.m. ET to discuss its fiscal year 2025 financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call.

    12/10/25 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care